Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Difei Lu

Peking University First Hospital, China

Title: Serum adropin and irisin levels are associated with obesity and metabolic indicators of obese patients

Biography

Biography: Difei Lu

Abstract

Introduction: Adropin and irisin are known as peptide hormones that regulate food intake and energy expenditure.

Aim: Our study aimed to investigate the association between adropin and irisin levels with obesity and metabolic indicators of obese patients in China.

Methodology & Theoretical Orientation: 70 overweight and obesity patients who were regularly followed up in the multidisciplinary clinic for obesity and 28 healthy individuals who visited physical examination center of Peking University First Hospital were enrolled in our study. Demographic data and obesity related metabolic indicators were collected during the first visit. Serum adropin and irisin levels were evaluated using EIA kit and ELISA kit, respectively. Statistical analysis was performed using SPSS 21.0.

Findings: Serum adropin levels reduced significantly in overweight/obesity group comparing with healthy individuals (6.92±2.43 vs. 7.97±1.84, p=0.043), while irisin levels showed no difference between the two groups. Adropin level was negatively associated with UA level in whole study individuals (r=-0.223, p=0.030) and positively associated with HDL-c level (r=0.214, p=0.043). In overweight/obesity subjects, adropin level was positively associated with proportion of daily protein intake (r=-0.278, p=0.029). Adropin levels decreased significantly in patients with metabolic syndrome (6.68±2.44 vs. 7.67±2.13, p=0.036), hyperuricemia (6.52±2.42 vs. 7.52±2.10, p=0.036), low-HDL (6.49±2.57 vs. 7.57±2.08, p=0.036) and NAFLD (6.73±2.36 vs. 7.68±2.10, p=0.039), comparing with those without the disease. Irisin levels reduced significantly in patients with NAFLD (11.43 vs. 13.18, p=0.043), comparing with those without NAFLD.

Conclusion & Significance: Adropin might play a beneficial role in obesity, lipid and uric acid metabolism, and the level decreased in obese, hyperuricemia, low-HDL or NAFLD patients. Irisin levels reduced in NAFLD patients.